Dramatic response of nivolumab-associated psoriasiform dermatitis to etoposide

There is a revolution in cancer therapy prompted by the resurgence of immunotherapy in the form of immune checkpoint inhibitors (ICPis) [1]. With the beneficial effects of this new understanding of how to harness the prowess of the immune system with therapeutic intent, it has also become clear that similar  to other modalities of cancer therapy, there are important side-effects associated to their use [2]. These side-effects are known as immune-related adverse events (irAEs) and are the result of an immunological imbalance introduced by the disruption of the immune system homoeostasis.

Source: European Journal of Cancer - December 13, 2018 Category: Cancer & Oncology Authors: Adan Rios, Putao Cen, Brian Dinh, Steven R. Mays, Anisha B. Patel Tags: Letter to the Editor Source Type: research